ClinicalTrials.gg
CompletedNCT05940402Updated Apr 4, 2025

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

A Phase 1 interventional study of Emraclidine in Renal Impairment, sponsored by AbbVie. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Renal Insufficiency by AbbVie — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AbbVie.

Started
2023
the only one that year
Phase 1
4 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Renal Insufficiency by AbbVie, this one is the only one that started in 2023, is one of 4 in phase 1, and was the 11th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 11 studies in Renal Insufficiency by AbbVie is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Renal Insufficiency by AbbVie as a file.
02

Study summary

The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal impairment relative to matched participants with normal renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. For All Participants

    • of ≥18.0 to 42.0 kilograms per meter square (kg/m\^2), inclusive, and a total body weight ≥50 kilograms (kg) (110 pounds [lbs]).
    • Sexually active women of must agree to use at least an acceptable method during the trial and for 7 days after the last dose of medicinal product (IMP).
  2. Additional Criteria for Participants With Normal Renal Function

    • Age that is within ±10 years of the median age for the renal impairment groups.
    • Body weight that is within ±15% of the median body weight for the renal impairment groups.
    • Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, , vital sign measurements, and laboratory test results, as evaluated by the investigator.
    • Normal renal function: Estimated (eGFR) ≥90 milliliter per minute (mL/min) determined using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Renal function assessed at Baseline (Check-in/Day -1) should not deviate more than 30% from the Screening value.
  3. Additional Criteria for Participants With Renal Impairment

    • Mild, moderate, or severe renal impairment based on eGFR determined using the 2021 CKD-EPI equation. Renal function assessed at Baseline (Check-in/Day -1) should not deviate more than 30% from the Screening value.
    • Stable disease, defined as no changes in disease status as documented by most recent eGFR assessment (within at least 3 months before Screening).
    • Stable concomitant medications for the management of individual participant's medical history; on a case-by-case basis, with input from the sponsor, participants receiving fluctuating concomitant medication/treatment may be considered if the underlying disease is under control.

Key Exclusion Criteria:

  1. For All Participants

    • "Yes" responses for any of the following items on the C-SSRS (within the individual's lifetime):

      • Suicidal Ideation Item 3 (Active Suicidal Ideation with Any Methods [Not Plan] without Intent to Act)
      • Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan)
      • Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent)
      • Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior) "Yes" responses for any of the following items on the C-SSRS (within past 12 months):
      • Suicidal Ideation Item 1 (Wish to be Dead)
      • Suicidal Ideation Item 2 (Non-Specific Active Suicidal Thoughts) Any "yes" response on Suicidal Ideation Item 1 or Item 2 that was within the individual's lifetime but not within the past 12 months should be discussed with the medical monitor prior to inclusion of the participant in the trial.
    • Serious risk of suicide in the opinion of the investigator is also exclusionary.
    • History of moderate to severe substance or alcohol-use disorder (excluding nicotine or caffeine) as per criteria within 12 months prior to signing the form (ICF).
    • Receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination or booster within 7 days of planned dosing.

    In addition, participants who plan to receive SARS-CoV-2 vaccination or booster while participating in the trial or for a minimum of 7 days (to cover at least 5 half-lives of IMP) after the last dose of investigational medicinal product (IMP) will be excluded.

    • Have recently been diagnosed with symptomatic coronavirus disease-2019 (COVID-19) or test positive (i.e., using polymerase chain reaction [PCR] or rapid antigen test) for SARS-CoV-2 within 15 days prior to signing the ICF.
  2. Additional Criteria for Participants With Normal Renal Function

    • Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus), (except for surgically excised non-melanomatous skin cancers or in situ cervical cancer, at the discretion of the investigator), hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
  3. Additional Criteria for Participants With Renal Impairment

    • Evidence of disease that is not explained by current/known medical history, i.e., organ dysfunction (including malignancies) or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with renal impairment and other underlying conditions.
    • Participants who have received an organ transplant or are currently waiting for an organ transplant and are listed on the national transplant list.
    • Participants who require dialysis
    • Participants with nephrotic syndrome.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Mild Renal Impairment

    Participants will receive a single oral dose of 10 milligrams (mg) emraclidine on Day 1.

    Drug: Emraclidine

  • Experimental
    Moderate Renal Impairment

    Participants will receive a single oral dose of 10 mg emraclidine on Day 1.

    Drug: Emraclidine

  • Experimental
    Severe Renal Impairment

    Participants will receive a single oral dose of 10 mg emraclidine on Day 1.

    Drug: Emraclidine

  • Experimental
    Normal Renal Function

    Participants will receive a single oral dose of 10 mg emraclidine on Day 1.

    Drug: Emraclidine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 5

  2. Maximum Observed Unbound Plasma Concentration (Cmax,u) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 5

  3. Area Under the Plasma Concentration-time Curve from Time Zero to t (AUC0-t) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 5

  4. Area Under the Unbound Plasma Concentration-time Curve from Time Zero to t (AUC0-t,u) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 5

  5. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 5

  6. Area Under the Unbound Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf,u) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 5

Secondary outcomes

  1. Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 15

  2. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values

    Time frame: Up to Day 5

  3. Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Up to Day 5

  4. Number of Participants With Clinically Significant Change in Laboratory Assessments

    Time frame: Up to Day 5

  5. Number of Participants With Clinically Significant Change in Physical and Neurological Examination Results

    Time frame: Up to Day 5

  6. Changes in Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

    Time frame: Up to Day 5

07

Study locations

5 sites
  • Tustin, California
    Tustin, California 92780, United States
  • Miami, Florida
    Miami, Florida 33014, United States
  • Miami, Florida
    Miami, Florida 33136, United States
  • Orlando, Florida
    Orlando, Florida 32808, United States
  • Knoxville, Tennessee
    Knoxville, Tennessee 37920, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Dec 2024, 16 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 16 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2023
First posted
Jul 11, 2023
StartActual
Jul 24, 2023
Primary completionActual
Dec 19, 2024
CompletionActual
Dec 19, 2024
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05940402
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Jul 24, 2023
Primary completion
Dec 19, 2024
Completion
Dec 19, 2024
Last update
Apr 4, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion